Viscosupplementation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End Use By Region & Competition, 2021-2031F

The Global Viscosupplementation Market is set to grow from USD 5.15 Billion in 2025 to USD 8.46 Billion by 2031, achieving an 8.62% CAGR. Viscosupplementation is a medical procedure that involves injecting hyaluronic acid into synovial joints to restore natural viscoelasticity and reduce pain, primarily for osteoarthritis. This market expansion is largely driven by the rapidly aging global population and a concurrent increase in degenerative joint diseases, which necessitate effective non-surgical management. Furthermore, a growing patient preference for minimally invasive therapies that can postpone orthopedic surgery also fuels demand for these products. For instance, Versus Arthritis reported that in 2025, over 20 million people in the United Kingdom lived with a musculoskeletal condition, underscoring the substantial disease burden driving this sector.

A significant hurdle hindering market growth is the inconsistent and restrictive reimbursement landscape for hyaluronic acid injections across different healthcare systems. Regulatory bodies and insurers frequently scrutinize the clinical efficacy of these treatments against their cost, often resulting in limited insurance coverage and high out-of-pocket expenses, which in turn restrict patient access and reduce overall market penetration.

Market Driver

The Global Viscosupplementation Market is being fundamentally reshaped by a strategic shift toward single-injection regimens, addressing both patient convenience and clinical efficiency. Healthcare providers are increasingly adopting cross-linked hyaluronic acid formulations that require only one administration, thereby reducing clinic visits and minimizing risks associated with multi-dose courses. This preference for high-molecular-weight, single-shot therapies directly correlates with robust segment growth, as evidenced by Bioventus's double-digit revenue growth in its Pain Treatments vertical in Q4 and FY 2024, primarily driven by its single-injection Durolane product. Such adoption patterns underscore a broader industry pivot towards treatments that optimize orthopedic practice resources while enhancing patient adherence to therapy.

Simultaneously, escalating obesity rates are acting as a critical catalyst for market expansion by accelerating the onset of degenerative joint diseases. Excess body mass imposes severe mechanical load on weight-bearing joints, causing rapid cartilage erosion that necessitates non-surgical intervention like viscosupplementation to delay invasive procedures. According to the World Obesity Federation's 'World Obesity Atlas 2025', the global number of adults living with obesity is projected to reach 1.13 billion by 2030. This expanding demographic of patients with lifestyle-induced joint disorders is fueling demand for effective pain management solutions, reflected in the financial performance of key market players like Seikagaku Corporation, which saw its Pharmaceutical business segment sales increase 6.1% year-on-year in fiscal 2024.

Market Challenge

A critical barrier impeding the growth of the Global Viscosupplementation Market is the restrictive and inconsistent reimbursement landscape for hyaluronic acid injections. Insurance providers and regulatory bodies frequently scrutinize the clinical efficacy of these intra-articular treatments in relation to their costs, often leading to stringent coverage policies or outright payment denials. This financial stringency shifts the burden directly to patients, resulting in substantial out-of-pocket expenses that make the therapy economically inaccessible for many individuals. Consequently, the market experiences reduced adoption rates, as patients who cannot afford the procedure are compelled to forgo treatment despite its clinical necessity.

This economic limitation severely constrains market penetration, even amid increasing demand. For example, the Arthritis Foundation reported that in 2024, over 32.5 million adults in the United States were affected by osteoarthritis. Despite this vast patient population requiring non-surgical management, the lack of consistent insurance support prevents the market from effectively leveraging this volume. As a result, the disparity between disease prevalence and treatment affordability restricts revenue generation and hinders the overall expansion of the sector.

Market Trends

The market is being reshaped by the increasing adoption of combination therapies that feature corticosteroids and hyaluronic acid, providing patients with immediate pain relief along with sustained viscoelastic improvement. This trend effectively addresses the delayed onset of action often seen with standalone viscosupplements, thus improving patient satisfaction and compliance through a dual-mechanism approach. Market players are actively capitalizing on this demand by expanding their international portfolios of these hybrid formulations. For example, Anika Therapeutics reported a 17% increase in Commercial Channel revenue in 2024, significantly driven by the strong performance of its International OA Pain Management segment, which markets the combination product Cingal.

Concurrently, the industry is making a decisive shift towards non-animal derived, bio-fermented hyaluronic acid sources to minimize the risks of avian protein allergies and ensure consistent product purity. This transition enables manufacturers to scale production efficiently while meeting the stricter safety profiles mandated by global regulatory bodies. Leading pharmaceutical companies are heavily investing in research to optimize these biotechnological manufacturing processes and broaden their product portfolios. Fidia Farmaceutici, for instance, invested €29.3 million in R&D during the fiscal year to support its innovation pipeline, including advancements in its proprietary hyaluronic acid technology platform, as stated in its May 2025 press release.

Key Market Players

• Sanofi SA
• Seikagaku Corporation
• Smith & Nephew PLC.
• Lifecore Biomedical, LLC.
• Fidia Farmaceutici S.p.A
• F.Hoffmann-La Roche Ltd.
• LG Life Sciences Ltd.
• Ferring Pharmaceutical B.V.
• Zimmer Biomet Holdings Inc
• Anika Therapeutics, Inc.

Report Scope

In this report, the Global Viscosupplementation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viscosupplementation Market, By Product Type

• Single Injection
• Three Injection
• Five Injection

Viscosupplementation Market, By End Use

• Hospitals
• Orthopedic Clinics/ASCs

Viscosupplementation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viscosupplementation Market.

Available Customizations:

Global Viscosupplementation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).